Individuals affected by one of the many inherited neurodegenerative diseases exhibit several very intriguing biological conundrums. While these individuals are born with the disease-causing mutation, in most instances the neurological symptoms do not manifest until relatively late in life after a substantial period of normal neurological function. Furthermore, the disease-causing genes encode proteins that are often widely expressed throughout the CNS and other tissues, yet each disease is characterized by a set of pathological alterations that are restricted to, at least initially, a unique subset of neurons.
Among the neurodegenerative diseases that display these biological riddles are the so-called polyglutamine diseases. To date, eight inherited neurodegenerative diseases-Huntington disease (HD), the autosomal dominant spinocerebellar ataxias (SCA1, SCA2, SCA3, SCA6, and SCA7), spinobulbar muscular atrophy (SBMA), and dentatorubropallidoluysian atrophy (DRPLA)-share a common mutational mechanism: the expansion of a CAG trinucleotide repeat located within the coding region of the disease gene (Zoghbi & Orr, 2000) . The CAG expansion leads to the production of a mutant protein with an extended tract of glutamines, thus their designation as polyglutamine diseases. The normal functions of these proteins remain unknown, except for AR (SBMA) and CACNA1A (SCA6), which code for the androgen receptor and the a 1A voltage-dependent calcium channel, respectively. All eight polyglutamine disorders are progressive, often manifesting in midlife, with an increase in neuronal dysfunction and eventual neuronal loss 10 -20 years after onset. Other features that characterize this group of diseases are the inverse relationship between the number of CAG repeats on expanded alleles and the age of onset and severity of disease and an intergenerational instability that leads to further repeat expansions, earlier age of onset, and more rapid disease progression in affected offspring of affected parents.
